Pharma IQ Members

100 results
of 10
April 18, 2017 by Ash Rishi
Ash Rishi
Patient education is an important factor in disease self-management, and when handled properly it has been found to have a significant, positive impact on improving patient outcomes.
Tags: Pharmaceutical, medicines, cure, treatment, drug, medicine, disease, condition, illness, sickness, patient, pharma, bio pharma, drug development, healthcare,
March 29, 2017 by Pharma IQ
Pharma IQ
As the term patient centricity continues to buzz in the pharma industry, data has emerged stating that US physicians have experienced an overwhelming amount of confusion from patients around direct to consumer (DTC) adverts.
Tags: medicine, medicines, healthcare, drugs, pharma, pharmaceuticals, cure, patient, patient centricity, adverts, advertising, physicians, confusion, DTC
February 14, 2017 by Social Monsters.org
default profile icon
After years of resistance, the health care and pharmaceutical industries are now accelerating full steam towards the cloud. In fact, the global health care cloud computing market, valued at $4.5 billion in 2016, will reach $9.5 billion by 2020. Here are the dominant benefits that are drawing these giants to the cloud.
Tags:
February 7, 2017 by Ash Rishi
Ash Rishi
When it comes to manoeuvrability and nimble response, large companies have more in common with ocean liners than speedboats. Policies are agreed, marketing strategies planned, and future developments or projects set in motion months or years in advance.
Tags:
February 6, 2017 by
Pharma IQ
One healthcare official told me yesterday, 'Yes, drug prices need to come down. At the same time, though, we do need to ensure that pharma companies do keep the incentive to innovate.' And I've got the boss of one of the biggest healthcare companies in the world sitting right next to me, that's Joe Jimenez the CEO of Novartis.
Tags:
January 13, 2017 by Dr Steven Bradshaw
Dr Steven Bradshaw
At the start of 2016, the industry predicted many market access trends. As we come to the end of the year, let us look at the market access trends predicted at the start of 2016. How have these predictions unfolded so far and what will be the next set of trends for the coming year?
Tags:
January 13, 2017 by Pharma IQ
Pharma IQ
With several patent expiries in 2015 and 2016, there was high expectation that a significant portion of the biologics market would shift to biosimilar use by 2016, especially in the areas of diabetes, rheumatology, and in tendering markets. I
Tags:
December 20, 2016 by Pharma IQ
Pharma IQ
The last quarter of 2016 was certainly not short of activity with a £84 million pharma fine issued in regards to drug pricings, an investigation into a suspected supply chain breach and numerous therapeutic approvals.
Tags:
100 results
of 10